The presence of an EGFR mutation significantly increased VTE risk in a prospective cohort study of 131 glioblastoma patients (adjusted HR 2.19, 95% CI: 1.15–4.19) but not in a larger retrospective cohort study of 324 glioblastoma patients (HR 1.27, 95% CI: 0.56–2.87) [43,44]. The gene discussed is EGFR; the disease is glioblastoma.